Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).

"CONFLICT OF INTEREST J.S., T.H.P., E.P.P., and M.W.P. are consultants for MTPA. S.A. is an employee of MTPA. W.A. is a former employee of MTPA. S.L. is an employee of MTDA. J.Z. is under contract with MTPA."

"Funding information Mitsubishi Tanabe Pharma America, Inc."

"Study 19 was a randomized, double‐blind, parallel‐group, placebo‐controlled study. The details of study methodology, ethical study conduct, patient selection (inclusion and exclusion criteria), end points, and prospective statistical analyses have been previously described in detail (http://clinicaltrials.org: NCT01492686)., Briefly, patients were randomized to either edaravone (60 mg) or placebo for 24 weeks followed by a 24‐week open‐label extension period. The primary efficacy end point was the change in ALSFRS‐R score from baseline to the end of week 24."